Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...

Like tens of thousands of Massachusetts residents, community college professor Carolyn McGrath has been paying for medicine ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Mass General Brigham researchers found that by December 2023, more than 1 in 3 of the medications being started for type 2 diabetes treatment were GLP-1RA-based medications, such as semaglutide or tir ...

Some of the more than a dozen states that cover GLP-1 drugs like Wegovy, Ozempic and Zepbound through Medicaid are scrambling ...

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability ...

About half of Americans "strongly" or "somewhat" favor having Medicare and Medicaid cover weight-loss drugs for people who ...

Opinion: McDermott, Will & Emery's Byron Kalogerou and Meredith Cullen Schwartz say demand in the anti-obesity market and new ...

U.S. President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the federal government's Medicare program. The Centers for Medicare and ...

Proponents of coverage argued treating obesity can reduce longer-term costs by cutting down on heart attacks and other health ...

Joe Biden had proposed a rule in late November after Trump won re-election that would have extended coverage of drugs like Zepbound and ... and other serious health issues. The federal program ...